A detailed history of Massmutual Trust CO Fsb transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Massmutual Trust CO Fsb holds 374 shares of NBIX stock, worth $47,561. This represents 0.0% of its overall portfolio holdings.

Number of Shares
374
Previous 512 26.95%
Holding current value
$47,561
Previous $70,000 38.57%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 02, 2024

SELL
$114.58 - $153.15 $15,812 - $21,134
-138 Reduced 26.95%
374 $43,000
Q2 2024

Jul 02, 2024

BUY
$130.86 - $143.19 $20,283 - $22,194
155 Added 43.42%
512 $70,000
Q1 2024

Apr 09, 2024

BUY
$130.4 - $143.74 $1,434 - $1,581
11 Added 3.18%
357 $49,000
Q4 2023

Jan 03, 2024

BUY
$106.07 - $132.76 $954 - $1,194
9 Added 2.67%
346 $45,000
Q3 2023

Oct 03, 2023

BUY
$94.02 - $117.1 $8,085 - $10,070
86 Added 34.26%
337 $37,000
Q2 2023

Aug 01, 2023

BUY
$89.53 - $104.87 $6,446 - $7,550
72 Added 40.22%
251 $23,000
Q1 2023

Apr 11, 2023

BUY
$94.11 - $123.02 $1,223 - $1,599
13 Added 7.83%
179 $18,000
Q4 2022

Jan 06, 2023

BUY
$106.72 - $127.06 $640 - $762
6 Added 3.75%
166 $20,000
Q3 2022

Oct 07, 2022

BUY
$92.03 - $107.81 $9,110 - $10,673
99 Added 162.3%
160 $17,000
Q2 2022

Jul 07, 2022

SELL
$75.79 - $100.07 $833 - $1,100
-11 Reduced 15.28%
61 $6,000
Q1 2022

Apr 08, 2022

BUY
$72.45 - $94.81 $4,564 - $5,973
63 Added 700.0%
72 $7,000
Q4 2021

Feb 09, 2022

BUY
$79.65 - $106.22 $716 - $955
9 New
9 $1,000
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $576 - $810
-6 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $510 - $782
6 New
6 $1,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Massmutual Trust CO Fsb Portfolio

Follow Massmutual Trust CO Fsb and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massmutual Trust CO Fsb, based on Form 13F filings with the SEC.

News

Stay updated on Massmutual Trust CO Fsb with notifications on news.